Join our daily newsletter At The Bell to receive exclusive market insights
- ImpediMed (IPD) initiates its SOZO heart failure program at Advocate Health Care’s Heart Institute in Chicago
- ImpediMed says it has been able to leverage its existing footprint within the Advocate Aurora Health system to move forward with an initial heart failure program
- Managing Director and CEO of ImpediMed Richard Carreon says after significant COVID-19 delays it is great to initiate the SOZO heart failure program at such a highly respected medical institution
- ImpediMed shares are up 4.76 per cent, trading at 11 cents at 3:09 pm AEST
ImpediMed (IPD) has initiated its SOZO heart failure program at Advocate Health Care’s Heart Institute in Chicago.
AdvocateAuroraHealth, the conglomerate of Advocate Health Care in Illinois and Aurora Health Care in Wisconsin, is made up of 26 hospitals and more than 500 sites of care.
The introduction of SOZO is being championed by Ali Valika, an interventional cardiology specialist, with the aim of optimising fluid levels in heart failure patients, both in clinics and after discharge.
SOZO is a non-invasive bioimpedance spectroscopy device which can deliver a precise snapshot of fluid status and tissue composition in a patient in less than 30 seconds.
ImpediMed said it was able to leverage its existing footprint within the Advocate Aurora Health system to move forward with an initial heart failure program.
The Advocate Aurora Health system currently has 10 SOZO devices under a Lymphoedema Prevention Program.
Managing Director and CEO of ImpediMed Richard Carreon said after significant COVID-19 delays it was great to initiate the SOZO heart failure program at such a highly respected medical institution.
“We are expecting other hospitals to initiate SOZO heart failure programs shortly, adding to the clinical and reimbursement evidence required to underpin widespread commercialisation,” Mr Carreon said.
ImpediMed shares were up 4.76 per cent, trading at 11 cents at 3:09 pm AEST.
